Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

por Avanzi, Mauro P., Yeku, Oladapo, Li, Xinghuo, Wijewarnasuriya, Dinali P., van Leeuwen, Dayenne G., Cheung, Kenneth, Park, Hyebin, Purdon, Terence J., Daniyan, Anthony F., Spitzer, Matthew H., Brentjens, Renier J.
Publicado 2018

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

por Rafiq, Sarwish, Yeku, Oladapo O., Jackson, Hollie J., Purdon, Terence J., van Leeuwen, Dayenne G., Drakes, Dylan J., Song, Mei, Miele, Matthew M., Li, Zhuoning, Wang, Pei, Yan, Su, Xiang, Jingyi, Ma, Xiaojing, Seshan, Venkatraman E., Henderickson, Ronald C., Liu, Cheng, Brentjens, Renier J.
Publicado 2018